2′ and 3′-nucleoside prodrugs for treating
View Patent ↗2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses , including hepatitis C virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions, methods and uses are provided for the treatment of Flaviviridae infection, including HCV infection, that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
1. A method for the treatment of a hepatitis C virus infection in a host, comprising admisistering to a host infected with a hepatitis C virus an effective treatment amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has Formula (V):
wherein:
R 1 is H or phosphate;
R 2 and R 3 are independently H, phosphate, acyl or an amino acid residue, wherein at least one of R 2 and R 3 is acyl or an amino acid residue;
X 1 and H or CH 3 ; and
Y is hydrogen, bromo, chloro, fluoro, iodo, NH 2 or OH.
2. The method of claim 1 , wherein the compound or pharmaceutically acceptable salt thereof, is in the form of a dosage unit.
3. The method of claim 2 , wherein the dosage unit contains 50 to 1000 mg or 1 to 50 mg of the compound.
4. The method of claim 2 , wherein the dosage unit is a tablet or capsule.
5. The method of claim 1 , wherein the host is a human.
6. The method of claim 1 , wherein the wherein the compound or pharmaceutically acceptable salt thereof, is at least 85% by weight of the β-D-isomer.
7. The method of claim 1 , wherein the compound, or pharmaceutically acceptable salt thereof, is at least 90% by weight of the β-D-isomer.
8. The method of claim 1 , wherein the compound, or pharmaceutically acceptable salt thereof, is at least 95% by weight of the β-D-isomer.
9. The method of claim 1 , wherein the compound is in the form of a pharmaceutically acceptable salt selected from the group consisting of a tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorate, α-ketoglutarate, α-glycerophosphate, formate, fumarate, propionate, glycolate, lactate, pyruvate, oxalate, maleate, salicylate, sulfate, nitrate, bicarbonate, carbonate salts, hydrobromate, hydrochloride, di-hydrochloride, and phosphoric acid salt.
10. The method of claim 9 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.
11. The method of claim 9 , wherein the pharmaceutically acceptable salt is a di-hydrochloride salt.
12. The method of claim 1 , wherein Y is hydrogen.
13. The method of claim 1 , wherein Y is bromo, chioro, fluoro or iodo.
14. The method of claim 1 , wherein X 1 is H.
15. The method of claim 1 , wherein R 1 is H.
16. The method of claim 1 , wherein R 2 is a residue of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine.
17. The method of claim 1 , wherein R 2 is a residue of a naturally occurring or synthetic α, β, γ, or δ amino acid.
18. The method of claim 1 , wherein R 2 is a residue of an amino acid in an L configuration.
19. The method of claim 1 , wherein R 2 is a residue of valine.
20. The method of claim 1 , wherein R 1 is mono, di or triphosphate.